메뉴 건너뛰기




Volumn 271, Issue 7274, 2003, Pages 646-648

Hormone replacement therapy: (2) Risks and benefis

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PLACEBO;

EID: 0345255747     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)

References (8)
  • 1
    • 0032547326 scopus 로고    scopus 로고
    • Randomised trial of oestrogen plus progesterone is secondary prevention of coronary heart disease in postmenopausal women
    • The heart and estrogen/progestin replacement study research group (HERS)
    • The heart and estrogen/progestin replacement study research group (HERS). Randomised trial of oestrogen plus progesterone is secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
    • (1998) JAMA , vol.280 , pp. 605-613
  • 2
    • 0037014584 scopus 로고    scopus 로고
    • Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
    • Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
    • (2002) JAMA , vol.288 , pp. 49-57
    • Grady, D.1    Herrington, D.2    Bittner, V.3    Blumenthal, R.4    Davidson, M.5    Hlatky, M.6
  • 3
    • 0037125379 scopus 로고    scopus 로고
    • Risks and benefits of estrogen plus progestin in healthy menopausal women. Principal results from the WHI randomised controlled trial
    • Writing group for the Women's Health Initiative (WHI) investigators
    • Writing group for the Women's Health Initiative (WHI) investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women. Principal results from the WHI randomised controlled trial. JAMA 2002;288:321-33.
    • (2002) JAMA , vol.288 , pp. 321-333
  • 4
    • 0042018741 scopus 로고    scopus 로고
    • Breast cancer and hormone replacement therapy in the Million Women Study
    • for the Million Women study collaborators
    • Beral V for the Million Women study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
    • (2003) Lancet , vol.362 , pp. 419-427
    • Beral, V.1
  • 5
    • 0003954079 scopus 로고    scopus 로고
    • Osteoporosis: Clinical guidelines for prevention and treatment
    • Royal College of Physicians Available at: www. rcplondon.ac.uk (accessed on 4 November)
    • Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. Available at: www. rcplondon.ac.uk (accessed on 4 November 2003).
    • (2003)
  • 6
    • 0030843969 scopus 로고    scopus 로고
    • Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
    • Collaborative group on hormonal factors in breast cancer
    • Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
    • (1997) Lancet , vol.350 , pp. 1047-1059
  • 7
    • 0031058448 scopus 로고    scopus 로고
    • Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
    • Beresford SA, Weiss N, Voigt L, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-61.
    • (1997) Lancet , vol.349 , pp. 458-461
    • Beresford, S.A.1    Weiss, N.2    Voigt, L.3    McKnight, B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.